Reversible ethambutol-induced optic neuropathy: report of a rare case

Main Article Content

Syntia Nusanti
Rasyidia Laksmita Putri
Dearaini Dearaini

Abstract

Background
Ethambutol (EMB) is one of the first-line anti-tuberculosis therapy. One of its precarious side effects is ethambutol-induced optic neuropathy (EON). The ocular manifestations of EON include painless loss of central vision and cecocentral scotomas in the visual field.


Case Description
A 60-year old man presented with gradual and painless visual loss since 3 months prior to visit. The accompanying symptoms were frequent headache without double vision and photophobia. He had been diagnosed with pulmonary tuberculosis (TB) for 9 months and consumed EMB for 7 months before being advised to discontinue. There was neither history of systemic diseases nor family history of neuropathy. Examination showed reduced visual acuity with positive relative afferent pupillary defect (RAPD) on right eye. Humphrey test showed bilateral generalized visual loss. Ocular computed tomography (OCT) showed retinal nerve fiber layer (RNFL) thickness was within normal limit. Magnetic resonance Imaging (MRI) brain indicated unremarkable result for optic neuropathy. Based on the examinations listed above, this patient was diagnosed as EON and EMB was stopped immediately. Patient was given oral citicoline 1000mg and zinc supplementation for one month. After 1 st and 3 rd month follow up, patient’s visual function was gradually improved. The ophthalmic examinations indicated recovery of the visual function.


Conclusions
This case suggested that an early detection and intervention in patient with EON has promising result in visual outcome. EON is a reversible optic neuropathy if the ocular toxicity is monitored closely among the tuberculosis patients who are prescribed EMB regiment.

Article Details

How to Cite
Nusanti, S., Putri, R. L., & Dearaini, D. (2022). Reversible ethambutol-induced optic neuropathy: report of a rare case. Universa Medicina, 41(3). Retrieved from https://univmed.org/ejurnal/index.php/medicina/article/view/1274
Section
Case Report

References

Kim JH, Yim J. Achievements in and challenges of tuberculosis control in South Korea. Emerg Infect Dis 2015;21:1913–20. doi: 10.3201/eid2111.141894.

World Health Organization. Global tuberculosis report 2013. Geneva: World Health Organization;2013.

Chamberlain PD, Sadaka A, Berry S. Ethambutol optic neuropathy. Curr Opin Ophthalmol 2017; 28:545-51. doi: 10.1097/ICU.0000000000000416.

Kim YJ, Lim SH, Kim U. Natural course and prognostic factors of ethambutol toxic optic neuropathy. Res Sq 2020;4–11. doi: 10.21203/rs.3.rs-76098/v1.

Chen S, Lin M, Sheu S. Incidence and prognostic factor of ethambutol-related optic neuropathy/ : 10-year experience in southern Taiwan. Kaohsiung J Med Sci 2015;31:358–62. doi: 10.1016/j.kjms.2015.05.004.

Sari RI. The effect of citicoline on ethambutol optic neuropathy: histopathology & immunohistochemistry analysis of retina ganglion cell damage level in rat model. [thesis]. Jakarta: Universitas Indonesia; 2016.

Bandyopadhyay S, Banerjee S, Bandyopadhyay S, Shamantha M, Biswas S. A prospective evaluation of ocular toxicity in patients receiving ethambutol as anti tubercular therapy. Sudan J Ophthalmol 2020;12:10–4. DOI: 10.4103/sjopthal.sjopthal_4_20.

Tang RA, Schiffman J, Cruz RA, Corsi G. Ethambutol: friend or foe?, Exp Rev Ophthalmol 2014;2:59-61. DOI: 10.1586/17469899.2014.898564.

Han J, Byun MK, Lee J, et al. Longitudinal analysis of retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in ethambutolinduced optic neuropathy. Graefe’s Arch Clin Exp Ophthalmol 2015;253:2293–9. doi: 10.1007/s00417-015-3150-8.

Kim KL, Park SP. Visual function test for early detection of ethambutol induced ocular toxicity at the subclinical level. Cutan Ocul Toxicol 2016; 35:228–32. doi: 10.3109/15569527.2015.1079784.

Pavan Taffner BM, Mattos FB, Cunha MCD, Saraiva FP. The use of optical coherence tomography for the detection of ocular toxicity by ethambutol. PLoS One 2018;13:e0204655. doi: 10.1371/journal.pone.0204655.

Sarkar S, Ganguly A, Sunwoo HH. Current overview of anti-tuberculosis drugs: metabolism and toxicities. Mycobact Dis 2016;6. doi:10.4172/2161-1068.1000209.

Erie JC, Good JA, Butz JA, Pulido JS. Reduced zinc and copper in the retinal pigment epithelium and choroid in age-related macular degeneration. Am J Ophthalmol 2009;147:276-82. http://dx.doi.org/10.1016/j.ajo.2008.08.014.

Chung H, Hee Y, Jin J, Sook K, Young J, Kim J. Ethambutol-induced toxicity is mediated by zinc and lysosomal membrane permeabilization in cultured retinal cells. Toxicol Appl Pharmacol 2009;235:163–70.

Kinoshita J, Iwata N, Maejima T, Kimotsuki T. Retinal function and morphology in monkeys with ethambutol-induced optic neuropathy. Invest Ophthalmol Vis Sci 2012;53:7052-62. doi: https://doi.org/10.1167/iovs.12-103082012;7052–62.